Study of plasma adiponectin level in patients with metabolic syndrome
Keywords:Metabolic syndrome, Adiponectin, Insulin resistance, Lipid profile
Background: The metabolic syndrome (MS) is a cluster of interrelated common clinical disorders, including hypertension, insulin resistance, glucose intolerance and dyslipidaemia, in addition to obesity. Central obesity accompanied by insulin resistance is a keyfactor in the development of metabolic syndrome (MS) and future macro vascular complications. Adiponectin is the most abundant peptide secreted by adipocytes, being a key component in the interrelationship between adiposity, insulin resistance and inflammation. Hypoadiponectimia has already been associated with the risk of the MS in several populations. Plasma adiponectin level was measured in the current study to clarify its role as a biomarker for metabolic syndrome (MS).
Methods: This study was conducted on 40 MS patients (Group I) compared with 20 age and sex matched healthy volunteers (Group II). All patients and controls were subjected to full medical history, clinical examination and laboratory investigations in addition to plasma adiponectin level.
Results: Plasma adiponectin levels were significantly lower in subjects with MS when compared with subjects with no diagnosis of MS. There was significant negative correlation between plasma adiponectin and age, waist circumference, body mass index, systolic blood pressure, diastolic blood pressure, fasting blood sugar, insulin resistance, serum insulin, and triglycerides. Also there was significant positive correlation between plasma adiponectin and HDL.
Conclusion: We conclude that adiponectin levels could help as a biomarker for cases of MS.
Kassi E, Pervanidou P, Kaltsas G, Chrousos G. Metabolic syndrome: definitions and controversies. BMC Med. 2011;48(9):13.
Grundy SM: Metabolic syndrome pandemic. Arterioscler Thromb Vasc Biol. 2008;28:629-36.
Moller DM, KAufman KD. Metabolic syndrome: a clinical and molecular perspective. Annual Review of Medicine. 2005;56:45– 62.
Hamdy O, Porramatikul S, Al-Ozairi E. Metabolic obesity: the paradox between visceral and subcutaneous fat. Curr Diabetes Rev. 2006;2:367–73.
Robinson K, Prins J, Venkatesh B. Clinical review: adiponectin biology and its role in inflammation and critical illness. Crit Care. 2011;15:221.
Hajer GR, Van Haeften TW, Visseren FL. Adipose tissue dysfunction in obesity, diabetes, and vascular diseases. Eur Heart J. 2008;29:2959–71.
Matsuzawa Y, Funahashi T, Kihara S, Shimomura I. Adiponectin and metabolic syndrome. Arterioscler Thromb Vasc Biol. 2004;24:29–33.
Lima Marcos M, Rosa Francisco J, Marín A, Romero-Vecchione E. Adiponectina y sus efectos pleiotrópicos en el sistema cardiovascular. Rev Venez Endocrinol Metab 2009;7:3–9.
Yamauchi T, Kadowaki T. Physiological and pathophysiological roles of adiponectin and adiponectin receptors in the integrated regulation of metabolic and cardiovascular diseases. Int J Obes (Lond). 2008,32(Suppl 7):S13–S18.
Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe K. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest. 2006;116:1784–92.
Silva TE, Colombo G, Schiavon LL: Adiponectin: A multitasking player in the field of liver diseases. Diabetes Metab. 2014;40:95–107.
Díez JJ, Iglesias P. The role of the novel adipocyte-derived hormone adiponectin in human disease. Eur J Endocrinol. 2003;148:293–300.
Hara K, Horikoshi M, Yamauchi T, Yago H, Miyazaki O, Ebinuma H, et al. Measurement of the high-molecular weight form of adiponectin in plasma is useful for the prediction of insulin resistance and metabolic syndrome. Diabetes Care. 2006;29:1357–62.
Kaser S, Tatarczyk T, Stadlmayr A, Ciardi C, Ress C, Tschoner A, et al. Effect of obesity and insulin sensitivity on adiponectin isoform distribution. Eur J Clin Invest. 2008;38:827–34.
Awazawa M, Ueki K, Inabe K, Yamauchi T, Kubota N, Kaneko K, et al. Adiponectin enhances insulin sensitivity by increasing hepatic IRS-2 expression via a macrophage-derived IL-6-dependent pathway. Cell Metab. 2011;13:401-12.
Gabrielsen JS, Gao Y, Simcox JA, Huang J, Thorup D, Jones D, et al. Adipocyte iron regulates adiponectin and insulin sensitivity. J Clin Invest. 2012;122:3529–40.
Pérez-Fontán M, Cordido F, Rodríguez-Carmona A, Peteiro J, García-Naveiro R, García-Buela J. Plasma ghrelin levels in patients undergoing haemodialysis and peritoneal dialysis. Nephrol Dial Transplant. 2004;19(8):2095-100.
DeUgarte CM, Bartolucci AA, and Azziz R. Prevalence of insulin resistance in the polycystic ovary syndrome using the homeostasis model assessment. 2005;83(5):1454-60.
Gavrila D, Salmeron D, Egea-Caparros JM, Huerta JM, Perez-Martinez A, Navarro C, et al. Prevalence of metabolic syndrome in Murcia region, a Southern European mediterranean area with low cardiovascular risk and high obesity. BMC Public Health. 2011;11:562.
Riediger N, Clara I. Prevalence of metabolic syndrome in the Canadian adult population. CMAJ. 2011;183:E1127–E1134.
Brooks N, Moore K, Clark R, Perfetti M, Trent C, Combs T. Do low levels of circulating adiponectin represent a biomarker or just another risk factor for the metabolic syndrome? Diabetes Obes Metab. 2007;9:246–58.
Tong G, Wang N, Leng J, Tong X, Shen Y, Yang J, et al. Common variants in adiponectin gene are associated with coronary artery disease and angiographical severity of coronary atherosclerosis in type 2 diabetes. Cardiovasc Diabetol. 2013;12:67.
Okamoto Y, Kihara S, Funahashi T, Matsuzawa Y, Libby P. Adiponectin: a key adipocytokine in metabolic syndrome. Clin Sci (Lond). 2006;110:267–78.
Xydakis AM, Case CC, Jones PH, Hoogeveen RC, Liu MY, Smith EO, et al. Adiponectin, inflammation, and the expression of the metabolic syndrome in obese individuals: the impact of rapid weight loss through caloric restriction. Journal of Clinical Endocrinology and Metabolism. 2004;89:2697–703.
Bacha F, Saad R, Gungor N, Arslanian SA. Adiponectin in youth: relationship to visceral adiposity, insulin sensitivity, and beta-cell function. Diabetes Care. 2004;27:547–52.
Santaniemi M, Kesa¨niemi YA,
Ukkola O. Low plasma adiponectin concentration is an indicator of the metabolic syndrome. European Journal of Endocrinology. 2006;155:745–50.
Thanakun S, Watanabe H, Thaweboon S, Izumi Y. Comparison of salivary and plasma adiponectin and leptin in patients with metabolic syndrome. Diabetology & Metabolic Syndrome. 2014;6:19.
Kawano J, Arora R. The role of adiponectin in obesity, diabetes, and cardiovascular disease. J Cardiometab Syndr. 2009,4:44–9.
Hui X, Lam KS, Vanhoutte PM, Xu A. Adiponectin and cardiovascular health: an update. Br J Pharmacol. 2012;165:574–90.
Lin HV, Kim JY, Pocai A, Rossetti L, Shapiro L, Scherer PE, et al. Adiponectin resistance exacerbates insulin resistance in insulin receptor transgenic/knockout mice. Diabetes. 2007;56:1969–76.
Fisman, Tenenbaum. Adiponectin: a manifold therapeutic target for metabolic syndrome, diabetes, and coronary disease? Cardiovascular Diabetology. 2014;13:103.